Jan 16 |
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium
|
Jan 3 |
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 2 |
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients
|
Dec 11 |
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium
|
Nov 21 |
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference
|
Nov 13 |
Leap Therapeutics GAAP EPS of -$0.51 beats by $0.07
|
Nov 13 |
Recap: Leap Therapeutics Q3 Earnings
|
Nov 13 |
Leap Therapeutics Reports Third Quarter 2023 Financial Results
|